Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals

被引:34
作者
Forward, KR [1 ]
Willey, BM
Low, DE
McGeer, A
Kapala, MA
Kapala, MM
Burrows, LL
机构
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Toronto, ON, Canada
关键词
D O I
10.1016/S0732-8893(01)00278-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Escherichia coli may become resistant to cephamycines and oxyimino cephalosporins by virtue of promotor and attenuator mutations or because they have acquired mobilized beta -lactamases from other grain-negative bacilli. This study examined Canadian strains to determine how often promotor and/or alternator mutations account for this mechanism of resistance and the extent to which clonal spread of these organisms has occurred. We sequenced the promotor and attenuator region of 30 strains resistant to cefoxitin. Twenty-two strains had promotor mutations, 26 had attenuator mutations. Most promotor mutations resulted either in a change in the -35 promotor region towards the E. coli sigma 70 consensus sequence or in the creation of a new consensus heximer upstream. Eight strains had mutations that increased the typical ampC 16-nucleotide spacer region to the consensus 17- or an 18-nucleotide sequence. Of the alternator mutations, most did not substantially affect the attenuator loop. Several of the mutations have previously been described in South Africa, Scandinavia, and France. There was evidence that strains bearing certain mutations were clonally disseminated however, the 11 strains bearing a complex set of attenuator mutations were not. The majority of cephamycin resistant E. coli strains in Toronto have attenuator and/or promotor mutations upstream of the chromosomal ampC gene. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 16 条
[1]   A novel type of AmpC β-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia [J].
Bauernfeind, A ;
Schneider, I ;
Jungwirth, R ;
Sahly, H ;
Ullmann, U .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1924-1931
[2]   Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244 [J].
Bret, L ;
Chaibi, EB ;
ChanalClaris, C ;
Sirot, D ;
Labia, R ;
Sirot, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2547-2549
[3]  
Caroff N, 1999, FEMS MICROBIOL LETT, V173, P459, DOI 10.1016/S0378-1097(99)00111-1
[5]   Transferable class C β-lactamases in Escherichia coli strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii AmpC β-lactamase [J].
Gazouli, M ;
Tzouvelekis, LS ;
Vatopoulos, AC ;
Tzelepi, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :419-425
[6]  
Hertz GZ, 1996, METHOD ENZYMOL, V273, P30
[7]   INVIVO REGULATION OF CHROMOSOMAL BETA-LACTAMASE IN ESCHERICHIA-COLI [J].
JAURIN, B ;
NORMARK, S .
JOURNAL OF BACTERIOLOGY, 1979, 138 (03) :896-902
[8]   THE ESCHERICHIA-COLI BETA-LACTAMASE ATTENUATOR MEDIATES GROWTH RATE-DEPENDENT REGULATION [J].
JAURIN, B ;
GRUNDSTROM, T ;
EDLUND, T ;
NORMARK, S .
NATURE, 1981, 290 (5803) :221-225
[9]   SEQUENCE ELEMENTS DETERMINING AMPC PROMOTER STRENGTH IN ESCHERICHIA-COLI [J].
JAURIN, B ;
GRUNDSTROM, T ;
NORMARK, S .
EMBO JOURNAL, 1982, 1 (07) :875-881
[10]   Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams [J].
Leggiadro, RJ .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1997, 11 (04) :875-&